179 related articles for article (PubMed ID: 35884431)
1. Comparative Efficacy of Tyrosine Kinase Inhibitors and Antibody-Drug Conjugates in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A Systematic Review and Network Meta-Analysis.
Wang Y; Xu H; Han Y; Wu Y; Wang J
Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884431
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of tyrosine kinase inhibitors for the treatment of patients with HER2-positive breast cancer with brain metastases: a systematic review and meta-analysis.
Nader-Marta G; Martins-Branco D; Agostinetto E; Bruzzone M; Ceppi M; Danielli L; Lambertini M; Kotecki N; Awada A; de Azambuja E
ESMO Open; 2022 Jun; 7(3):100501. PubMed ID: 35653982
[TBL] [Abstract][Full Text] [Related]
3. Tyrosine kinase inhibitors in HER2-positive breast cancer brain metastases: A systematic review and meta-analysis.
Yu Y; Huang K; Lin Y; Zhang J; Song C
Cancer Med; 2023 Jul; 12(14):15090-15100. PubMed ID: 37255389
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of tucatinib for HER2-positive metastatic breast cancer after HER2-targeted therapy: a network meta-analysis.
DeBusk K; Abeysinghe S; Vickers A; Nangia A; Bell J; Ike C; Forero-Torres A; Blahna MT
Future Oncol; 2021 Nov; 17(33):4635-4647. PubMed ID: 34463120
[TBL] [Abstract][Full Text] [Related]
5. Evaluating the clinical effectiveness and safety of various HER2-targeted regimens after prior taxane/trastuzumab in patients with previously treated, unresectable, or metastatic HER2-positive breast cancer: a systematic review and network meta-analysis.
Paracha N; Reyes A; Diéras V; Krop I; Pivot X; Urruticoechea A
Breast Cancer Res Treat; 2020 Apr; 180(3):597-609. PubMed ID: 32100144
[TBL] [Abstract][Full Text] [Related]
6. Comparative efficacy, safety, and acceptability of single-agent poly (ADP-ribose) polymerase (PARP) inhibitors in
Wang J; Zhang Y; Yuan L; Ren L; Zhang Y; Qi X
Aging (Albany NY); 2020 Nov; 13(1):450-459. PubMed ID: 33257598
[TBL] [Abstract][Full Text] [Related]
7. Round table discussion: strategies for the treatment of HER2-positive advanced breast cancer in the rising age of antibody-drug conjugates.
Yan Y; Li Q; Li J
Transl Breast Cancer Res; 2022; 3():18. PubMed ID: 38751515
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Anti-HER2 Agents in Combination With Chemotherapy for Metastatic HER2-Positive Breast Cancer Patient: A Network Meta-Analysis.
Zhang X; Leng J; Zhou Y; Mao F; Lin Y; Shen S; Sun Q
Front Oncol; 2021; 11():731210. PubMed ID: 34490125
[TBL] [Abstract][Full Text] [Related]
9. Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Current Treatment Standards and Future Perspectives.
Dormann C
Breast Care (Basel); 2020 Dec; 15(6):570-578. PubMed ID: 33447230
[TBL] [Abstract][Full Text] [Related]
10. Progression-free survival with endocrine-based therapies following progression on non-steroidal aromatase inhibitor among postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative metastatic breast cancer: a network meta-analysis.
Ayyagari R; Tang D; Patterson-Lomba O; Zhou Z; Xie J; Chandiwana D; Dalal AA; Niravath PA
Curr Med Res Opin; 2018 Sep; 34(9):1645-1652. PubMed ID: 29781326
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Pyrotinib Versus T-DM1 in HER2+ Metastatic Breast Cancer Patients Pre-Treated With Trastuzumab and a Taxane: A Bayesian Network Meta-Analysis.
Liao H; Huang W; Liu Y; Pei W; Li H
Front Oncol; 2021; 11():608781. PubMed ID: 34012912
[TBL] [Abstract][Full Text] [Related]
12. Treatment-related adverse events associated with HER2-Targeted antibody-drug conjugates in clinical trials: a systematic review and meta-analysis.
Fu Z; Liu J; Li S; Shi C; Zhang Y
EClinicalMedicine; 2023 Jan; 55():101795. PubMed ID: 36712893
[TBL] [Abstract][Full Text] [Related]
13. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
Giuliano M; Schettini F; Rognoni C; Milani M; Jerusalem G; Bachelot T; De Laurentiis M; Thomas G; De Placido P; Arpino G; De Placido S; Cristofanilli M; Giordano A; Puglisi F; Pistilli B; Prat A; Del Mastro L; Venturini S; Generali D
Lancet Oncol; 2019 Oct; 20(10):1360-1369. PubMed ID: 31494037
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Anti-HER2 Targeted Therapy for Metastatic HR-Positive and HER2-Positive Breast Cancer: A Bayesian Network Meta-Analysis.
Wu XM; Qian YK; Chen HL; Hu CH; Chen BW
Curr Oncol; 2023 Sep; 30(9):8444-8463. PubMed ID: 37754530
[TBL] [Abstract][Full Text] [Related]
15. Association of Cyclin-Dependent Kinases 4 and 6 Inhibitors With Survival in Patients With Hormone Receptor-Positive Metastatic Breast Cancer: A Systematic Review and Meta-analysis.
Li J; Huo X; Zhao F; Ren D; Ahmad R; Yuan X; Du F; Zhao J
JAMA Netw Open; 2020 Oct; 3(10):e2020312. PubMed ID: 33048129
[TBL] [Abstract][Full Text] [Related]
16. Progression-free Survival With First-line Endocrine-based Therapies Among Postmenopausal Women With HR+/HER2- Metastatic Breast Cancer:: A Network Meta-analysis.
Ayyagari R; Tang D; Patterson-Lomba O; Zhou Z; Xie J; Chandiwana D; Dalal AA; Niravath PA
Clin Ther; 2018 Apr; 40(4):628-639.e3. PubMed ID: 29609880
[TBL] [Abstract][Full Text] [Related]
17. CDK4/6 inhibitors versus PI3K/AKT/mTOR inhibitors in women with hormone receptor-positive, HER2-negative metastatic breast cancer: An updated systematic review and network meta-analysis of 28 randomized controlled trials.
Xu H; Wang Y; Han Y; Wu Y; Wang J; Xu B
Front Oncol; 2022; 12():956464. PubMed ID: 36091147
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Neratinib Plus Capecitabine in the Subgroup of Patients with Central Nervous System Involvement from the NALA Trial.
Hurvitz SA; Saura C; Oliveira M; Trudeau ME; Moy B; Delaloge S; Gradishar W; Kim SB; Haley B; Ryvo L; Dai MS; Milovanov V; Alarcón J; Kalmadi S; Cronemberger E; Souza C; Landeiro L; Bose R; Bebchuk J; Kabbinavar F; Bryce R; Keyvanjah K; Brufsky AM
Oncologist; 2021 Aug; 26(8):e1327-e1338. PubMed ID: 34028126
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Value of the Serum HER2 Extracellular Domain Level in Breast Cancer: A Systematic Review and Meta-Analysis.
Wu Y; Li L; Zhang D; Ma F
Cancers (Basel); 2022 Sep; 14(19):. PubMed ID: 36230471
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of First-Line Treatment Strategies for Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Bayesian Network Meta-Analysis.
Peng L; Lu D; Xia Y; Hong S; Selvaggi G; Stebbing J; Sun Y; Liang F
Front Oncol; 2021; 11():754768. PubMed ID: 34820326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
